title: Advanced glycation endproducts in diabetes and diabetic complications.
abstract: This review presents insights from studies of advanced glycation end products (AGEs) in humans and mice. Although the emphasis is on the effects of exogenous AGEs and the suppression of specific host defense mechanisms, AGEs are also formed intracellularly, where they may contribute to several normal intracellular functions. It is only when the overall levels of AGEs in the extracellular and the intracellular spaces exceeds the ability of the native antioxidant (and AGE) defenses that they pose a problem.
authors.affiliation: Departments of Geriatrics and Medicine, Division of Experimental Diabetes and Aging, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Place, Annenberg Building, Box 1640, New York, NY 10029, USA. Electronic address: helen.vlassara@mssm.edu.
authors.forename: Helen
authors.initials: H
authors.lastname: Vlassara
authors.forename: Gary E
authors.initials: GE
authors.lastname: Striker
mesh_terms: D000328:Adult; D000375:Aging / Q000378:metabolism; D000818:Animals; D002648:Child; D048909:Diabetes Complications / Q000188:drug therapy / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D051379:Mice; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism
chemical_list: D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic
keywords: Advanced glycation endproduct; Diabetes; Insulin resistance; Metabolism